dengue

Dengvaxia, approved by the FDA, is for individuals 9-16 in dengue-endemic areas. Controversy arose due to differing vaccine performance in those with and without previous dengue infection. The vaccine can lead to severe dengue in seronegative individuals and was misused in the Philippines, causing a vaccine hesitancy crisis. It’s only necessary if living in endemic areas.